← Leaderboards
Mark Leick
Massachusetts General Hospital
$595,456
Attributed
$595,456
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $297.7K · FY2024–25$500K$375K$250K$125K$0
'24
'25
Funding mix
By agency
NIH$595,456 · 1
By mechanism
K08$595,456 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Marcela Valderrama Maus$16,508,365
- E. Antonio Chiocca$34,514,665
- Rakesh K. Jain$48,476,214
- Max Jan$1,188,918
- Sara Barmettler$1,093,926
Others in their field
Other Rising Stars on “Advisory Committees”
- Brian Zavertnik · Palantir Technologies, Inc.$33,059,912
- Johanna Marizan-Ho · Palantir Technologies, Inc.$9,612,691
- Frank A Provenzano · St. Joseph'S Hospital And Medical Center$8,533,907
- Brian Todd Schaneberg · Illinois Institute Of Technology$6,784,113
- Burton Rochelson · Feinstein Institute For Medical Research$5,891,324
- Christine O'Connell · H. Lee Moffitt Cancer Ctr & Res Inst$5,494,823
Research focus
Advisory CommitteesAchyroclineAnti-Cancer ResearchAutocrineAngiogenesisBiologyBlocking FactorB Lymphoid MalignancyBostonCancer ModelAutomobile DrivingCardiovascular SystemCareer DevelopmentCar T Cell TherapyCd19 GeneCell BehaviorCell PhysiologyCell SecretionCell SurvivalCell TherapyCellular BiologyCellular ImmunotherapyCancer TherapyChimeric Antigen Receptor T Cells
Grant awards (2)
Targeted delivery of a VEGFâblocking scFv by CD70 CARâT cells to enhance antiâtumor activity in renal cell carcinoma$297,728
K08 · FY2025 · CA · contact PI
Targeted delivery of a VEGFâblocking scFv by CD70 CARâT cells to enhance antiâtumor activity in renal cell carcinoma$297,728
K08 · FY2024 · CA · contact PI